Dexcom Q1: strong growth and positive news

Nordic Semiconductor (Buy, TP: NOK160.00) - Not too bad given tail-end...

While implied guidance for H1 revenues is ~1–4% below our forecast and consensus, the underlying sequential performance is directionally in line with the broader set of peers to have reported to date. We find this growth and gross margin profile solid, given we are at the tail-end of the life of Nordic’s 10-year-old 55nm technology platform. Combined with the arguably unprecedented level of uncertainty for the company’s customers, we find it achieving a ~50% gross margin and accelerated Cellular...

Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales

We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.

Nordic Semiconductor ASA: 1 director

A director at Nordic Semiconductor ASA bought 20,090 shares at 102.500NOK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression

We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).

Soft Q1 growth from Logitech

14% drop seems like an overreaction

Q1 beat, but muted Q2 guidance

Q1 a nice dunk, outlook a wild shot

Pandora (Buy, TP: DKK1400.00) - Still shining, but potential pressure

We expect Pandora to report a solid start to the year, with 6.4% LFL growth (consensus 5.6%) in Q1e, but believe focus is more likely to be on the implications (direct and indirect) of tariffs and higher silver prices. However, we believe these concerns are more than priced in after recent share-price weakness. We reiterate our BUY, but have lowered our target price to DKK1,400 (1,550).

Telenor (Sell, TP: NOK140.00) - Q1e slightly below consensus

We have made only limited estimate changes (except for an accounting change for the treatment of write-offs in associates) and are slightly below consensus on Q1e revenues, service revenues, adj. EBITDA, net profit and FCF. With Nordics opex cuts looking set to be back-end loaded this year, we expect Q1 to be a relatively uneventful quarter. We will look for more clarity on lower-quality cash flow tailwinds with regard to Telenor’s ability to cover its dividends with FCF before M&A this year, wh...

Nordic Semiconductor (Buy, TP: NOK174.00) - Near-term momentum likely ...

While the effects of trade tensions and tariff upheaval remain uncertain, our discussions with industry sources suggest strong, improving order momentum in Q1. Moreover, we expect the recently announced 90-day tariff pause to drive pull-forward of US imports. This has led us to shift our estimates from H2 towards H1. Beyond tariff-induced pull-ins, Dexcom channel replenishment dynamics remain one company-specific source of uncertainty to watch, while we estimate a limited effect. We remain sligh...

Novo Nordisk (Buy, TP: DKK900.00) - Subdued prescription growth in Q1

We have updated our model with the latest IQVIA data, and see downside risk to Visible Alpha consensus. We see Q1e global sales for Wegovy of DKK17,898m (c2.2% below consensus) and Ozempic of DKK31,642m (c1.5% below consensus). While a reaffirmation of guidance could offer relief, we have lowered our target price, primarily on lower-than-expected GLP-1 sales. We reiterate our BUY but have cut our target price to DKK900 (1,040).

Everyone's in on the PW pre-party

Improving cash flows, but still pricey

Rich valuation and slowing momentum

The Pandora Jewellery Box - March 2025

A-rated TMT credit investments/Better credits at similar spreads

This report updates credit investors on opportunities in the single-A TMT space. We argue that the notes of Relx, Swisscom, and ASML look attractive. The notes of SAP and Telenor look to trade at fair value. We provide a summary of our general findings, followed by company descriptions.